secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2024-02-23T23:59:59+00:00
Accession:  0000950170-24-019416
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Atara CMO Joshi departs; consulting deal includes $180K milestone on tabelecleucel BLA approval
--------------------------------------------------------------------------------

- EVP, Chief Medical Officer Dr. Joshi terminated Feb 2, 2024 as part of reduction in force.
- Entered consulting agreement Feb 22, 2024: $3,000 monthly fee plus $300/hr for excess hours.
- Outstanding RSU equity awards will continue vesting during consulting term.
- Eligible for $180,000 payment upon FDA approval of tabelecleucel BLA.
- Consulting arrangement runs through January 31, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000095017024019416/0000950170-24-019416-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000095017024019416/atra-20240222.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-019416

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer